4DMedical

4DMedical ROCE

The Return on Capital Employed (ROCE) of 4DMedical (4DX.AX) as of Nov 3, 2026 is -33.77 %. In the previous year, Return on Capital Employed (ROCE) was -73.95 % — a change of -54.34% (higher).

ROCE

-33.77 %

YoY

-54.34%

Last updated:

In 2026, 4DMedical's return on capital employed (ROCE) was -33.77 %, a -54.34% increase from the -73.95 % ROCE in the previous year.

The 4DMedical ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
-154.04 AUD
Jan 1, 2020
135.16 AUD
Jan 1, 2021
-22.49 AUD
Jan 1, 2022
-61.75 AUD
Jan 1, 2023
-42.90 AUD
Jan 1, 2024
-39.43 AUD
Jan 1, 2025
-73.95 AUD
Jan 1, 2026
-33.77 AUD
The 4DMedical ROCE history
YEARROCEYoY
-33.77 %-54.34%
-73.95 %+87.54%
-39.43 %-8.08%
-42.90 %-30.54%
-61.75 %+174.57%
-22.49 %-116.64%
135.16 %-187.74%
-154.04 %+12.50%
-136.93 %-4.90%
-143.99 %+56.08%
-92.25 %+158.02%
-35.75 %0.00%
-35.75 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

4DMedical Stock analysis

What does 4DMedical do? 4DMedical Ltd. commercializes its XV Technology, a four-dimensional lung imaging platform, through FDA-cleared XV Lung Ventilation Analysis Software (XV LVA) and CT LVAS, delivered via a software-as-a-service model. The company sells these products to hospitals and clinics, including I-MED Radiology Network, which operates approximately 250 clinics nationwide. XV LVAS and CT LVAS reports are generated using the company’s software, leveraging existing hospital imaging equipment or the XV Scanner. The firm’s revenue comes from SaaS subscriptions and software licensing for its imaging solutions. I-MED Radiology Network is a key client, with 4DMedical initiating the commercial rollout of XV LVAS within its network. The company provides lung imaging technology to selected clinics across I-MED, utilizing the XV Scanner or existing hospital equipment. Revenue streams are derived from the SaaS delivery model, with no mention of additional products or services beyond XV LVA and CT LVAS. 4DMedical’s flagship technology powers dynamic lung ventilation analysis, enabling physicians to identify respiratory issues earlier. The company’s products are designed for use with existing hospital imaging systems, reducing the need for additional hardware. The primary buyers are medical imaging providers like I-MED, which integrate XV Technology into their diagnostic services for respiratory conditions. 4DMedical is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling 4DMedical's Return on Capital Employed (ROCE)

4DMedical's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing 4DMedical's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

4DMedical's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in 4DMedical’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about 4DMedical stock

Return on Capital Employed (ROCE) of 4DMedical is -33.77 % in 2026.

Return on Capital Employed (ROCE) of 4DMedical changed from -73.95 % to -33.77 %, representing a -54.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) 4DMedical since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s 4DMedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — 4DMedical

All Key Metrics — 4DMedical